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This review was derived from a presentation made on September 2, 
2016 for the first Academy Day presented by the Working Party 
on Immunohematology at the International Society of Blood 
Transfusion (ISBT) Congress in Dubai. The focus of this review is to 
provide a brief overview of the clinical significance of blood group 
antibodies. Blood group antibodies can be naturally occurring 
(e.g., anti-A and anti-B through exposure to naturally occurring 
red blood cell [RBC] antigen-like substances) or can occur via 
exposure to foreign (donor) RBC antigens through previous 
transfusions, transplants, or exposure to fetal RBCs during or 
after pregnancy. However, not all blood group antibodies are 
clinically significant. Clinically significant blood group antibodies 
can cause adverse events after blood component transfusion or 
transplantation and/or can cause hemolytic disease of the fetus 
and newborn. Immunohematology 2018;34:4–6.
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Red blood cells (RBCs) carry numerous protein and 
carbohydrate antigens on their surface. In 2016, the 
International Society of Blood Transfusion recognized 346 
RBC antigens.1 These antigens can provoke an immune 
response that may lead to the development of antibodies. Such 
antibodies, directed at RBC antigens, can be produced through 
exposure to naturally occurring RBC antigen-like substances 
or exposure to foreign (donor) RBC antigens through previous 
transfusions, transplants, or exposure to fetal cells during or 
after pregnancy. Naturally occurring anti-A and anti-B are 
the only RBC antibodies normally found in human serum 
or plasma. All other antibodies are unexpected and can 
be divided into alloantibodies (an antibody to an antigen 
that an individual lacks) and autoantibodies (an antibody 
to an individual’s own antigen[s]). The role of blood group 
antibodies in blood transfusion, transplantation, hemolytic 
disease of the fetus and newborn (HDFN), and, in some cases, 
hemolytic anemia are reviewed in previous publications and 
summarized here.2–5
Blood Component Transfusion
The presence of antibodies directed against the blood group 
antigens in the transfused component (major incompatibility) 
or antibodies in the transfused product directed against the 
recipient’s blood group antigens (minor incompatibility) may 
lead to the destruction of RBCs and manifest as a hemolytic 
transfusion reaction (HTR). In HTRs, hemolysis may be 
intravascular or extravascular.
Intravascular HTR occurs rapidly, with cell destruction 
within a few minutes. This event is caused by IgM antibodies 
that activate the complement pathway, which leads to 
formation of a membrane-activating complex that punctures 
the RBC membrane and subsequently releases hemoglobin 
into the plasma, with severe signs and symptoms of hemolysis 
(described subsequently). The most common antibodies 
causing intravascular HTR are of the ABO blood group system 
(anti-A, anti-B, and anti-AB), but antibodies of other blood 
group systems have also been occasionally implicated.
Extravascular HTRs can be immediate (occurring within 
a few hours of transfusion) or delayed (occurring within a few 
days of transfusion) and are caused by IgG antibodies that do 
not bind complement (e.g., antibodies to Rh system antigens), 
or that bind complement at levels that do not lead to the 
formation of membrane activating complex (e.g., antibodies 
to Kidd or Duffy system antigens). RBCs coated with IgG or 
C3b are phagocytized by the macrophages in the spleen or 
sequestered by the liver macrophages. Usually, immediate 
extravascular HTRs occur in the presence of antibodies to ABO 
blood group antigens and have similar signs as intravascular 
HTRs but are milder. 
Delayed transfusion reactions (DTRs) usually occur in 
patients who were previously alloimmunized to an antigen but 
whose antibody titers have dropped to levels not detected by 
serologic tests or to levels insufficient to produce immediate 
hemolysis. In DTRs, the presence of the antigen in the 
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transfused product results in an anamnestic response within a 
few days, resulting in the clearance of the donor’s RBCs. These 
reactions may present with no clinical signs and may only be 
detected by serologic methods (delayed serologic transfusion 
reactions) or as delayed hemolytic transfusion reactions 
(DHTRs) with mild signs and few symptoms. These reactions 
may also result in fever, fall in hemoglobin levels, jaundice, 
and hemoglobinuria. In some cases, immune destruction of 
transfused RBCs may have no obvious pathological effects, 
yet these are detrimental because they reduce the efficacy of 
the transfusion. Severe manifestations (e.g., disseminated 
intravascular coagulation, renal failure) are rarely seen.
Destruction of Autologous RBCs (Autoimmune 
Hemolytic Anemias)
Autoimmune hemolytic anemias are a group of disorders 
in which the malfunction of the body’s immune system leads to 
development of antibodies against the individual’s own RBCs 
(autologous) and may lead to destruction of RBCs with release of 
hemoglobin into the plasma. These disorders can be idiopathic 
or secondary to a disease (e.g., systemic lupus erythematosus, 
lymphoma) or to drugs (e.g., alpha methyldopa, penicillin), the 
mechanisms of which are poorly understood and are reviewed 
elsewhere.6–10 These antibodies frequently react with all RBCs 
tested, although in some cases, specificity to antigens of high 
prevalence can be determined. Certain clinical conditions may 
also be associated with autoantibodies (e.g., antibodies to the I 
antigen after viral infection or autoantibodies to the P antigen 
in paroxysmal cold hemoglobinuria).
Transplantation
Many blood group antigens are expressed on tissues 
other than RBCs. ABO antigens are expressed on most tissues 
and, because anti-A and anti-B occur naturally in the plasma, 
these antigens play a major role in transplantation. In solid 
organ transplantation, antibodies in the recipient directed at 
donor antigens result in immune reactions that may cause 
rejection of the transplanted organ. In hematopoietic stem 
cell transplantation (HSCT), hematopoietic cells can be 
transplanted from a donor of any blood group to a recipient of 
any blood group. Consequently, HSCT can result in a matched 
transplant from an ABO-compatible donor or a mismatched 
transplant from a donor with antigens to which the recipient 
has antibodies (major mismatch), from a donor who will 
produce antibodies to the recipient’s RBCs (minor mismatch), 
or from a bidirectional mismatch in which both the donor’s 
and recipient’s RBCs produce antibodies against each other’s 
RBCs. In a mismatched HSCT, the donor’s hematopoietic 
cells will give rise to a new blood group in the recipient. Such 
mismatched HSCTs can result in immediate hemolysis at the 
time of graft infusion (more common with marrow transplants 
containing large amounts of RBCs) or delayed complications, 
such as hemolysis at the time of engraftment, pure RBC 
aplasia, delayed engraftment, or failure to engraft because of 
the presence of ABO antibodies or passenger lymphocytes.11
Hemolytic Disease of the Fetus and Newborn
HDFN is a potentially fatal alloimmune reaction caused 
by maternal antibodies that cross the placenta to the fetus, 
where they initiate immune destruction of RBCs in utero or 
during the neonatal period. These maternal antibodies are 
restricted to IgG because antibodies of other classes are not 
transported across the placental barrier. Maternal antibodies 
may have developed in response to prior exposure to paternal 
antigens [e.g., anti-D due to exposure of D– mother to a D+ 
fetus] or through previous blood transfusions [e.g., anti-K and 
-Jka in a K–, Jk(a–) woman]. Clinically, the severity of HDFN 
varies from mild neonatal jaundice that can be treated by 
phototherapy, to severe in utero anemia requiring intrauterine 
and/or post-delivery transfusions, to fetal or neonatal death.
Classifying RBC Antibodies
RBC antibodies can be directed at any of the more than 
300 known RBC antigens, although not all of them may 
cause the reactions just discussed. One clinical approach is 
to classify these antibodies into four categories: (1) clinically 
significant antibodies; (2) clinically insignificant antibodies; 
(3) antibodies that are clinically insignificant unless they are 
reactive at 37°C; and (4) antibodies whose clinical significance 
is unknown or that have occasional case reports of being 
clinically significant (Table 1). For evaluation of antibodies 
in this last category, curated literature can be found at the 
Notify Library Web site (www.notifylibrary.org), an online 
publically accessible database of adverse outcomes collected 
and analyzed by editorial groups of international experts, 
regulators, and clinicians.12
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Incidence of RBC Alloimmunization, HTRs, and 
Role of Hemovigilance
It is estimated that RBC antibodies occur in less than 
0.3 percent of normal blood donors,13 although the rate of 
alloimmunization increases in hospitalized patients who 
have received a blood transfusion.5,14 This rate is significantly 
higher in certain patient populations (e.g., transfusion-
dependent patients with sickle cell disease or thalassemia4,15). 
Alloimmunization was shown to be the third leading cause 
of transfusion-associated deaths in the United States and the 
UK. Data are generated from ongoing hemovigilance studies 
reported by various national agencies such as the Center for 
Biologics Evaluation and Research (CBER) of the U.S. Food 
and Drug Administration (FDA),16 the UK’s Serious Hazards of 
Transfusion (SHOT) annual report,17 and the Hemovigilance 
Activity Report of the French National Agency for Medicine 
and Health Product Safety.18 The Notify Library has only 
recently begun to add cases from the literature and reporting 
authorities; nevertheless, it serves as a ready resource for 
reviewing alloimmunization related to RBC antigens resulting 
from transfusion, pregnancy, and transplantation.
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Table 1. Selected RBC antibodies and their clinical significance






when reactive at 37°C
Unknown or variable 
clinical significance
ABO Cha, Rga Lea, Leb Yta
D, C, c, E, e Xga M, N Gya
K, k Csa P1 Hy
Fya, Fyb Kna Lub Sda
Jka, Jkb McCa, Yka A1 Ge
S, s JMH Bg
Vel Lua
Agreement does not exist in the literature for all antigens in all categories, 
and this list is not inclusive of all alloantibodies to blood group antigens.
RBC = red blood cell.
